Mr. Johnson Brings
Over 35 Years of Financial and Operating Experience to
Leadership Team
DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company")
today announced that Philip Johnson
has been appointed Executive Vice President and Chief Financial
Officer, effective March 1, 2024. Mr.
Johnson succeeds Renée Galá, who was promoted to President and
Chief Operating Officer in October 2023.
Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of
financial experience, most recently leading Eli Lilly and Company's
treasury and investor relations operations as Group Vice President
of Finance. In his new role, Mr. Johnson will oversee financial
reporting, accounting, tax, treasury, risk management, financial
planning and analysis, information services and facilities. He will
also oversee the Company's investor relations and corporate
development functions.
"Phil's deep financial acumen, strategic mindset and proven
leadership abilities are an ideal fit for Jazz. Phil's appointment
follows a comprehensive search process to identify the right
financial leader as we continue to execute against our strategy to
grow and diversify our global business," said Bruce Cozadd, Chairman and Chief Executive
Officer of Jazz Pharmaceuticals. "I am thrilled to welcome Phil to
Jazz and look forward to working closely with him to deliver
enhanced shareholder value."
"Jazz is a highly respected company with a strong financial
foundation and significant opportunities for growth and value
creation. It is exciting to join an innovative and science-driven
organization deeply committed to addressing the unmet needs of
patients who may have limited treatment options," said Phil Johnson. "I am thrilled to bring my
cross-functional expertise to my new role and build upon the team's
momentum to continue to grow and diversify Jazz's global
business."
About Philip
Johnson
Mr. Johnson has over 35 years of financial
experience, most recently spending nearly three decades at Eli
Lilly and Company where he held several senior leadership positions
around the world in the Finance organization. In his last position,
Phil served as Lilly's Group Vice President of Finance, where he
led the Company's treasury and investor relations operations. In
this role, he was also responsible for financial and negotiation
support for Lilly's business development activities and driving
Lilly's efforts with the financial community to drive positive
social and economic change for underrepresented groups. Phil
previously spent over 10 years as Lilly's Senior Vice President of
Investor Relations, where he worked in close collaboration with the
CEO and CFO to build deep relationships with the investment
community. Prior to his tenure at Lilly, he was a consultant at
McKinsey & Company and worked in a variety of finance roles at
other firms, primarily in mergers and acquisitions. Phil currently
serves on several Boards and Committees, including the Indiana Chamber of Commerce and the
Indianapolis Urban League. He also serves on the Board of Directors
of Equity 1821, Lynx Capital and AMR Action Fund and is an Advisory
Committee member for Jumpstart Nova and Sixty8 Capital. Phil holds
a Bachelor of Science in Finance from the University of Illinois and a Master of Management
from the Kellogg School of Management at Northwestern University.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals
plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose
purpose is to innovate to transform the lives of patients and their
families. We are dedicated to developing life-changing medicines
for people with serious diseases—often with limited or no
therapeutic options. We have a diverse portfolio of marketed
medicines and novel product candidates, from early- to late-stage
development, in neuroscience and oncology. Within these therapeutic
areas, we are identifying new options for patients by actively
exploring small molecules and biologics, and through innovative
delivery technologies and cannabinoid science. Jazz is
headquartered in Dublin, Ireland
and has employees around the globe, serving patients in nearly 75
countries. Please visit www.jazzpharmaceuticals.com for more
information.
Contacts:
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Strategic Brand Engagement
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Logo -
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-appoints-philip-johnson-as-chief-financial-officer-302066701.html